id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2008-N-0546-0009,FDA,FDA-2008-N-0546,Agency Information Collection Activities; Proposed Collection; Comment Request; Pet Food Early Warning Recall Rational Questionnaire as Part of the MedWatchPlus,Notice,N-Notice,2009-12-30T05:00:00Z,2009,12,2009-12-30T05:00:00Z,2010-01-30T04:59:59Z,2009-12-30T17:57:40Z,E9-30872,0,0,0900006480a741c2
FDA-2009-N-0664-0131,FDA,FDA-2009-N-0664,Medical Device Interoperability; Public Workshop,Notice,NM-Notice of Meeting,2009-12-30T05:00:00Z,2009,12,2009-12-30T05:00:00Z,,2009-12-30T17:44:57Z,E9-30871,0,0,0900006480a740cd
FDA-2009-N-0664-0130,FDA,FDA-2009-N-0664,Advisory Committees; Tentative Schedule of Meetings for 2010,Notice,N-Notice,2009-12-30T05:00:00Z,2009,12,2009-12-30T05:00:00Z,,2009-12-30T17:39:27Z,E9-30973,0,0,0900006480a74087
FDA-2009-N-0664-0132,FDA,FDA-2009-N-0664,Second Annual Sentinel Initiative Public Workshop,Notice,NM-Notice of Meeting,2009-12-30T05:00:00Z,2009,12,2009-12-30T05:00:00Z,,2009-12-30T17:49:10Z,E9-30971,0,0,0900006480a740d2
FDA-2009-D-0591-0001,FDA,FDA-2009-D-0591,Guidance to Pharmacies on Advance Compounding of Tamiflu Oral Suspension to Provide for Multiple Prescriptions;Availability,Notice,NAD-Notice of Availability of Data,2009-12-29T05:00:00Z,2009,12,2009-12-29T05:00:00Z,,2009-12-29T14:32:34Z,E9-30750,0,0,0900006480a7313d
FDA-2009-D-0600-0001,FDA,FDA-2009-D-0600,Draft Guidance for Industry on Tobacco Health Document Submission; Availability,Notice,Notice of Availability,2009-12-28T05:00:00Z,2009,12,2009-12-28T05:00:00Z,2010-01-23T04:59:59Z,2016-09-09T14:32:45Z,E9-30657,0,0,0900006480a72053
FDA-2009-N-0664-0129,FDA,FDA-2009-N-0664,Gastrointestinal Drugs Advisory Committee Notice of Meeting,Notice,NM-Notice of Meeting,2009-12-23T05:00:00Z,2009,12,2009-12-23T05:00:00Z,,2009-12-23T19:25:45Z,E9-30442,0,0,0900006480a704a2
FDA-2008-D-0399-0006,FDA,FDA-2008-D-0399,International Conference on Harmonisation: Guidance on Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the International Conference on Harmonisation Regions  Annex 5: Disintegration Test General Chapter,Notice,NAD-Notice of Availability of Data,2009-12-23T05:00:00Z,2009,12,2009-12-23T05:00:00Z,,2009-12-23T19:06:42Z,E9-30441,0,0,0900006480a70631
FDA-2009-D-0013-0004,FDA,FDA-2009-D-0013,International Conference on Harmonisation: Guidance on Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the International Conference on Harmonisation Regions,Notice,NAD-Notice of Availability of Data,2009-12-22T05:00:00Z,2009,12,2009-12-22T05:00:00Z,,2009-12-22T16:28:44Z,E9-30326,0,0,0900006480a6f728
FDA-2009-D-0588-0001,FDA,FDA-2009-D-0588,Guidance for Industry on the Timeframe for Submission of Tobacco Health Documents; Availability,Notice,NAD-Notice of Availability of Data,2009-12-21T05:00:00Z,2009,12,2009-12-21T05:00:00Z,,2009-12-22T15:59:22Z,E9-30297,0,0,0900006480a6ef9e
FDA-2003-M-0501-0001,FDA,FDA-2003-M-0501,Medical Devices; Availability of Safety and Effectiveness Summaries for Premarket Approval Applications,Notice,N-Notice,2009-12-18T05:00:00Z,2009,12,2009-12-18T05:00:00Z,,2025-04-16T19:38:47Z,03-27119,0,0,09000064804a2b25
FDA-2009-N-0575-0001,FDA,FDA-2009-N-0575,Meetings: Incorporation of New Science Into Regulatory Decisionmaking Within the Center for Devices and Radiological Health,Notice,NM-Notice of Meeting,2009-12-18T05:00:00Z,2009,12,2009-12-18T05:00:00Z,2010-02-25T04:59:59Z,2009-12-18T15:14:35Z,E9-30114,0,0,0900006480a6de81
FDA-2009-D-0574-0001,FDA,FDA-2009-D-0574,International Conference on Harmonisation; Draft Guidance on Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the International Conference on Harmonisation Regions,Notice,NAD-Notice of Availability of Data,2009-12-17T05:00:00Z,2009,12,2009-12-17T05:00:00Z,2010-02-17T04:59:59Z,2009-12-17T20:33:56Z,E9-29988,0,0,0900006480a6ca37
FDA-2009-F-0570-0001,FDA,FDA-2009-F-0570,"Lallemand, Inc.; Filing of Food Additive Petition",Notice,NFL-Notice of Filing,2009-12-17T05:00:00Z,2009,12,2009-12-17T05:00:00Z,,2009-12-17T19:55:48Z,E9-29961,0,0,0900006480a6c9d7
FDA-2009-N-0664-0127,FDA,FDA-2009-N-0664,Oncologic Drugs Advisory Committee; Notice of Meeting,Notice,NM-Notice of Meeting,2009-12-17T05:00:00Z,2009,12,2009-12-17T05:00:00Z,,2009-12-17T19:59:52Z,E9-29989,0,0,0900006480a6ca01
FDA-2009-D-0573-0001,FDA,FDA-2009-D-0573,International Conference on Harmonisation; Draft Guidance on Addendum to International Conference on Harmonisation S6,Notice,NAD-Notice of Availability of Data,2009-12-17T05:00:00Z,2009,12,2009-12-17T05:00:00Z,2010-02-02T04:59:59Z,2009-12-17T20:30:17Z,E9-29991,0,0,0900006480a6ca36
FDA-2009-N-0665-0074,FDA,FDA-2009-N-0665,New Animal Drugs for Use in Animal Feeds; Ractopamine; Tylosin,Notice,Notice of Final Rule,2009-12-17T05:00:00Z,2009,12,2009-12-17T05:00:00Z,,2013-07-09T16:15:47Z,E9-29998,0,0,0900006480a6ca39
FDA-2009-N-0664-0128,FDA,FDA-2009-N-0664,"Food and Drug Administration Clinical Trial Requirements, Regulations, Compliance and Good Clinical Practices; Public Workshop",Notice,NM-Notice of Meeting,2009-12-17T05:00:00Z,2009,12,2009-12-17T05:00:00Z,,2009-12-17T20:10:36Z,E9-30017,0,0,0900006480a6ca05
FDA-2009-D-0579-0001,FDA,FDA-2009-D-0579,International Conference on Harmonisation; Draft Guidance on Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the International,Notice,NAD-Notice of Availability of Data,2009-12-17T05:00:00Z,2009,12,2009-12-17T05:00:00Z,2010-02-17T04:59:59Z,2009-12-17T19:32:00Z,E9-29990,0,0,0900006480a6c715
FDA-2009-N-0665-0071,FDA,FDA-2009-N-0665,New Animal Drugs; Change of Sponsor; Ketamine - Final Rule,Notice,Notice of Final Rule,2009-12-16T05:00:00Z,2009,12,2009-12-16T05:00:00Z,,2014-07-11T16:32:48Z,E9-29888,0,0,0900006480a6bb3c
FDA-2009-N-0665-0072,FDA,FDA-2009-N-0665,Implantation or Injectable Dosage Form New Animal Drugs; Florfenicol,Notice,Notice of Final Rule,2009-12-16T05:00:00Z,2009,12,2009-12-16T05:00:00Z,,2013-07-09T16:24:11Z,E9-29875,0,0,0900006480a6bb82
FDA-1981-D-0064-0001,FDA,FDA-1981-D-0064,DEFECT ACTION LEVELS FOR HISTAMINE IN TUNA; AVAILABILITY OF GUIDE,Notice,Notice of Data Availability,2009-12-14T05:00:00Z,2009,12,2009-12-14T05:00:00Z,,2026-01-30T22:34:45Z,,0,0,09000064805af3df
FDA-2009-N-0293-0001,FDA,FDA-2009-N-0293,Peter Xuong Lam: Debarment Order,Notice,N-Notice,2009-12-14T05:00:00Z,2009,12,,,2009-12-14T16:56:58Z,E9-29715,0,0,0900006480a6a1b2
FDA-1995-D-0298-0001,FDA,FDA-1995-D-0298,Notice of Availability of Data  - NAD,Notice,NAD-Notice of Availability of Data,2009-12-14T05:00:00Z,2009,12,2009-12-14T05:00:00Z,1995-09-06T03:59:59Z,2009-12-14T17:42:41Z,,0,0,09000064805998f0
FDA-2009-N-0665-0067,FDA,FDA-2009-N-0665,New Animal Drugs; Change of Sponsor; Azaperone,Notice,Notice of Final Rule,2009-12-11T05:00:00Z,2009,12,2009-12-11T05:00:00Z,,2013-07-09T18:17:50Z,E9-29494,0,0,0900006480a692a1
FDA-2008-N-0424-0004,FDA,FDA-2008-N-0424,Postmarketing Safety Reporting for Combination Products; Extension of Comment Period,Notice,NPR-Notice of Proposed Rule-Making,2009-12-11T05:00:00Z,2009,12,2009-12-11T05:00:00Z,2010-01-30T04:59:59Z,2011-06-11T16:27:47Z,E9-29493,0,0,0900006480a692a4
FDA-1998-D-0025-0036,FDA,FDA-1998-D-0025,Guidance on Current Good Manufacturing Practice for Positron Emission Tomography Drugs; Availability,Notice,NAD-Notice of Availability of Data,2009-12-10T05:00:00Z,2009,12,2009-12-10T05:00:00Z,,2024-11-12T04:49:38Z,E9-29286,1,0,0900006480a6845a
FDA-2004-N-0449-0003,FDA,FDA-2004-N-0449,Current Good Manufacturing Practice for Positron Emission Tomography Drugs; Final Rule,Notice,Notice of Final Rule,2009-12-10T05:00:00Z,2009,12,2009-12-10T05:00:00Z,,2015-12-10T15:21:51Z,E9-29285,0,0,0900006480a6840e
FDA-2009-N-0561-0001,FDA,FDA-2009-N-0561,Electronic Margin of Safety and NonClinical Toxicology Study Data Submission; Notice of Pilot Project,Notice,N-Notice,2009-12-10T05:00:00Z,2009,12,2009-12-10T05:00:00Z,2010-03-11T04:59:59Z,2009-12-10T15:35:48Z,E9-29419,0,0,0900006480a684bb
FDA-2006-D-0362-0005,FDA,FDA-2006-D-0362,Guidance for Industry on Patient-Reported Outcome Measures: Use in Medical Product Development To Support Labeling Claims; Availability,Notice,NAD-Notice of Availability of Data,2009-12-09T05:00:00Z,2009,12,2009-12-09T05:00:00Z,,2009-12-09T17:15:22Z,E9-29273,0,0,0900006480a66be8
FDA-2009-N-0569-0001,FDA,FDA-2009-N-0569,Approved Tobacco Retailer Training Program; Request for Comments,Notice,N-Notice,2009-12-09T05:00:00Z,2009,12,2009-12-09T05:00:00Z,2010-01-09T04:59:59Z,2010-01-20T17:06:47Z,E9-29288,0,0,0900006480a66b8a
FDA-2009-N-0664-0126,FDA,FDA-2009-N-0664,Meetings: Anesthetic and Life Support Drugs Advisory Committee,Notice,NM-Notice of Meeting,2009-12-08T05:00:00Z,2009,12,2009-12-08T05:00:00Z,,2009-12-08T15:43:55Z,E9-29211,0,0,0900006480a66771
FDA-2009-N-0664-0125,FDA,FDA-2009-N-0664,Meetings: Oncologic Drugs Advisory Committee,Notice,N-Notice,2009-12-08T05:00:00Z,2009,12,2009-12-08T05:00:00Z,,2009-12-08T15:45:20Z,E9-29208,0,0,0900006480a66745
FDA-2009-F-0525-0001,FDA,FDA-2009-F-0525,Filing of Food Additive Petition (Animal Use) Kemira Oyj; Formic Acid,Notice,NFL-Notice of Filing,2009-12-07T05:00:00Z,2009,12,2009-12-07T05:00:00Z,2010-01-07T04:59:59Z,2009-12-07T16:23:09Z,E9-29049,0,0,0900006480a64b02
FDA-2009-D-0539-0001,FDA,FDA-2009-D-0539,Draft Guidance for Industry on Assay Development for Immunogenicity Testing of Therapeutic Proteins; Availability,Notice,Notice of Availability,2009-12-04T05:00:00Z,2009,12,2009-12-04T05:00:00Z,2010-02-03T04:59:59Z,2016-04-11T14:24:08Z,E9-28960,0,0,0900006480a62b67
FDA-2009-D-0542-0001,FDA,FDA-2009-D-0542,"Draft Guidance for Industry: Factors That Distinguish Liquid Dietary Supplements From Beverages, Considerations Regarding Novel Ingredients, and Labeling for Beverages and Other Conventional Foods; Availability",Notice,NAD-Notice of Availability of Data,2009-12-04T05:00:00Z,2009,12,2009-12-04T05:00:00Z,2010-02-03T04:59:59Z,2009-12-04T16:37:20Z,E9-28926,0,0,0900006480a62af4
FDA-2008-P-0560-0004,FDA,FDA-2008-P-0560,"Determination That MESANTOIN (Mephenytoin) Tablets, 100 Milligrams, was not Withdrawn From Sale for Reasons of Safety or Effectiveness",Notice,N-Notice,2009-12-03T05:00:00Z,2009,12,2009-12-03T05:00:00Z,,2009-12-03T16:23:23Z,E9-28872,0,0,0900006480a62024
FDA-2008-P-0330-0004,FDA,FDA-2008-P-0330,"Determination That ABILIFY DISCMELT (Aripiprazole) Orally Disintegrating Tablets, 20 Milligrams and 30 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness",Notice,N-Notice,2009-12-03T05:00:00Z,2009,12,2009-12-03T05:00:00Z,,2009-12-03T16:28:45Z,E9-28871,0,0,0900006480a6203c
FDA-2009-N-0554-0001,FDA,FDA-2009-N-0554,Agency Information Collection Activities; Proposed Collection; Comment Request; Manufactured Food Regulatory Program Standards,Notice,N-Notice,2009-12-02T05:00:00Z,2009,12,2009-12-02T05:00:00Z,2010-02-02T04:59:59Z,2009-12-02T20:33:26Z,E9-28834,0,0,0900006480a61db7
FDA-1982-P-0018-0393,FDA,FDA-1982-P-0018,Reclassify of Electroconvulsive Therapy Device,Notice,Notice of Intent,2009-12-02T05:00:00Z,2009,12,2009-12-02T05:00:00Z,1983-06-07T03:59:59Z,2024-12-17T14:01:40Z,83-8595,0,0,0900006480a61b8f
FDA-1982-P-0018-0400,FDA,FDA-1982-P-0018,Withdrawal of Certain Proposed Rules and Other Proposed Actions,Notice,Withdrawal,2009-12-02T05:00:00Z,2009,12,2009-12-02T05:00:00Z,,2025-01-07T16:11:00Z,04-26234,0,0,0900006480a61cb3
FDA-1982-P-0018-0399,FDA,FDA-1982-P-0018,Withdrawal of Certain Proposed Rules and Other Proposed Actions; Notice of Intent,Notice,Notice of Intent,2009-12-02T05:00:00Z,2009,12,2009-12-02T05:00:00Z,2003-07-22T03:59:59Z,2025-01-07T15:49:26Z,03-9865,0,0,0900006480a61caf
FDA-2009-D-0466-0001,FDA,FDA-2009-D-0466,Draft Compliance Policy Guide Sec. 527.300 Dairy Products-Microbial Contaminants and Alkaline Phosphatase Activity (Compliance Policy Guide 7106.08); Availability,Notice,NAD-Notice of Availability of Data,2009-12-01T05:00:00Z,2009,12,2009-12-01T05:00:00Z,2010-02-02T04:59:59Z,2009-12-01T17:53:51Z,E9-28756,0,0,0900006480a60f4f
FDA-2009-D-0524-0024,FDA,FDA-2009-D-0524,Guidance for Industry on Listing of Ingredients in Tobacco Products; Availability,Notice,Notice of Availability,2009-12-01T05:00:00Z,2009,12,2009-12-01T05:00:00Z,,2016-10-06T15:58:32Z,E9-28747,0,0,0900006480a60dfe
FDA-2007-D-0369-0033,FDA,FDA-2007-D-0369,Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,Notice,NAD-Notice of Availability of Data,2009-12-01T05:00:00Z,2009,12,2009-12-01T05:00:00Z,2010-02-02T04:59:59Z,2024-11-12T04:48:26Z,E9-28593,1,0,0900006480a60ef1
FDA-2009-N-0220-0009,FDA,FDA-2009-N-0220,Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Experimental Studies of Nutrition Symbols on Food Packages,Notice,N-Notice,2009-12-01T05:00:00Z,2009,12,,,2009-12-01T17:36:23Z,E9-28699,0,0,0900006480a60eea
FDA-2009-N-0664-0124,FDA,FDA-2009-N-0664,Meetings: Pediatric Advisory Committee; Correction,Notice,NCR-Notice of Correction,2009-11-30T05:00:00Z,2009,11,2009-11-30T05:00:00Z,,2009-11-30T15:10:02Z,E9-28448,0,0,0900006480a6026c
FDA-2009-D-0563-0001,FDA,FDA-2009-D-0563,"Draft Guidance for Industry and Food and Drug Administration Staff; Preliminary Timetable for the Review of Applications for Modified Risk Tobacco Products Under the Federal Food, Drug, and Cosmetic Act; Availability",Notice,NAD-Notice of Availability of Data,2009-11-27T05:00:00Z,2009,11,2009-11-27T05:00:00Z,2010-02-26T04:59:59Z,2009-11-27T16:13:56Z,E9-28515,0,0,0900006480a5f56b
FDA-2009-N-0664-0123,FDA,FDA-2009-N-0664,Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting,Notice,NM-Notice of Meeting,2009-11-27T05:00:00Z,2009,11,2009-11-27T05:00:00Z,,2009-11-27T15:43:51Z,E9-28302,0,0,0900006480a5f50d
FDA-2008-D-0413-0015,FDA,FDA-2008-D-0413,Guidance for Industry on Residual Solvents in Drug Products Marketed in the United States; Availability,Notice,Notice of Availability,2009-11-25T05:00:00Z,2009,11,2009-11-25T05:00:00Z,,2020-05-11T22:59:33Z,E9-28247,0,0,0900006480a5e954
FDA-2009-N-0288-0001,FDA,FDA-2009-N-0288,Anthony W. Albanese: Debarment Order,Notice,N-Notice,2009-11-23T05:00:00Z,2009,11,,,2009-11-23T15:40:25Z,E9-28084,0,0,0900006480a5c872
FDA-2009-N-0281-0001,FDA,FDA-2009-N-0281,Niaja Kane: Debarment Order,Notice,N-Notice,2009-11-23T05:00:00Z,2009,11,,,2009-11-23T15:45:57Z,E9-28083,0,0,0900006480a5c8d3
FDA-2009-N-0556-0001,FDA,FDA-2009-N-0556,Agency Information Collection Activities; Proposed Collection; Comment Request; Records and Reports Concerning Experience WithApproved New Animal Drugs,Notice,N-Notice,2009-11-20T05:00:00Z,2009,11,2009-11-20T05:00:00Z,2009-12-22T04:59:59Z,2009-11-20T15:19:13Z,E9-27956,0,0,0900006480a5b482
FDA-2008-D-0614-0004,FDA,FDA-2008-D-0614,Guidance for Industry on Changes to Approved New Animal Drug Applications-New Animal Drug Applications Versus Category II SupplementalNew Animal Drug Applications; Availability,Notice,NAD-Notice of Availability of Data,2009-11-20T05:00:00Z,2009,11,2009-11-20T05:00:00Z,,2024-11-07T22:11:17Z,E9-27926,1,0,0900006480a5b4d9
FDA-2009-N-0665-0059,FDA,FDA-2009-N-0665,Oral Dosage Form New Animal Drugs; Sulfadimethoxine - Final Rule,Notice,Notice of Final Rule,2009-11-20T05:00:00Z,2009,11,,,2014-01-08T12:43:29Z,E9-27885,0,0,0900006480a5b477
FDA-2009-D-0533-0001,FDA,FDA-2009-D-0533,"Draft Guidance for Industry: Recommendations for the Assessment of Blood Donor Suitability, Blood Product Safety, and Preservation of the Blood Supply in Response to Pandemic (H1N1) 2009 Virus; Availability",Notice,NAD-Notice of Availability of Data,2009-11-19T05:00:00Z,2009,11,2009-11-19T05:00:00Z,2009-12-04T04:59:59Z,2009-11-19T15:09:58Z,E9-27729,0,0,0900006480a5ab15
FDA-2009-N-0664-0121,FDA,FDA-2009-N-0664,Vaccines and Related Biological Products Advisory Committee; Notice of Meeting,Notice,NM-Notice of Meeting,2009-11-19T05:00:00Z,2009,11,2009-11-19T05:00:00Z,,2009-11-19T15:00:23Z,E9-27728,0,0,0900006480a5aac9
FDA-2009-N-0664-0122,FDA,FDA-2009-N-0664,Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,Notice,NM-Notice of Meeting,2009-11-19T05:00:00Z,2009,11,2009-11-19T05:00:00Z,,2009-11-19T15:04:24Z,E9-27741,0,0,0900006480a5ab09
FDA-2009-N-0665-0057,FDA,FDA-2009-N-0665,New Animal Drugs for Use in Animal Feeds; Melengestrol; Monensin,Notice,Notice of Final Rule,2009-11-19T05:00:00Z,2009,11,2009-11-19T05:00:00Z,,2013-07-09T18:15:25Z,E9-27744,0,0,0900006480a5ab33
FDA-2009-N-0143-1063,FDA,FDA-2009-N-0143,Risk Evaluation and Mitigation Strategies for Certain Opioid Drugs; Notice of Public Meeting,Notice,NM-Notice of Meeting,2009-11-18T05:00:00Z,2009,11,2009-11-18T05:00:00Z,2009-11-28T04:59:59Z,2009-11-18T17:39:41Z,E9-27718,0,0,0900006480a58ff2
FDA-2009-N-0251-0003,FDA,FDA-2009-N-0251,Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; User Fee Cover Sheet; Form FDA 3397,Notice,N-Notice,2009-11-18T05:00:00Z,2009,11,2009-11-18T05:00:00Z,,2009-11-18T17:12:14Z,E9-27719,0,0,0900006480a59071
FDA-2009-N-0393-0007,FDA,FDA-2009-N-0393,Acrylamide in Food; Request for Comments and for Scientific Data and Information; Extension of Comment Period,Notice,NEC-Notice of Extension,2009-11-18T05:00:00Z,2009,11,2009-11-18T05:00:00Z,2010-01-26T04:59:59Z,2009-11-18T19:44:04Z,E9-27692,0,0,0900006480a58fc6
FDA-2009-N-0545-0001,FDA,FDA-2009-N-0545,"Agency Information Collection Activities; Proposed Collection; Comment Request; Biological Products: Reporting of Biological Product Deviations and Human Cells, Tissues, and Cellular and Tissue-Based Product Deviations in Manufacturing; Form FDA 3486 and Addendum 3486A",Notice,N-Notice,2009-11-18T05:00:00Z,2009,11,2009-11-18T05:00:00Z,2010-01-20T04:59:59Z,2009-11-18T19:42:09Z,E9-27716,0,0,0900006480a58fc5
FDA-2009-N-0535-0001,FDA,FDA-2009-N-0535,"Agency Information Collection Activities; Proposed Collection; Comment Request; ""Real Time"" Surveys of Consumers",Notice,N-Notice,2009-11-18T05:00:00Z,2009,11,2009-11-18T05:00:00Z,2010-01-20T04:59:59Z,2009-11-18T17:17:04Z,E9-27659,0,0,0900006480a59000
FDA-2009-N-0291-0002,FDA,FDA-2009-N-0291,Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Infectious Disease Issues in Xenotransplantation,Notice,N-Notice,2009-11-18T05:00:00Z,2009,11,2009-11-18T05:00:00Z,,2009-11-18T19:39:06Z,E9-27658,0,0,0900006480a58ff1
FDA-2009-C-0543-0001,FDA,FDA-2009-C-0543,Sauflon Pharmaceuticals Ltd.; Filing of Color Additive Petition,Notice,NFL-Notice of Filing,2009-11-18T05:00:00Z,2009,11,2009-11-18T05:00:00Z,,2009-11-18T17:23:15Z,E9-27629,0,0,0900006480a59037
FDA-2009-N-0664-0120,FDA,FDA-2009-N-0664,Anti-Infective Drugs Advisory Committee; Amendment of Notice,Notice,N-Notice,2009-11-18T05:00:00Z,2009,11,2009-11-18T05:00:00Z,,2009-11-18T17:43:36Z,E9-27693,0,0,0900006480a59038
FDA-2009-N-0532-0001,FDA,FDA-2009-N-0532,Agency Information Collection Activities; Proposed Collection; Comment Request; Experimental Study of Nutrition Facts Label Formats,Notice,N-Notice,2009-11-18T05:00:00Z,2009,11,2009-11-18T05:00:00Z,2010-01-20T04:59:59Z,2009-11-18T19:40:46Z,E9-27720,0,0,0900006480a58fea
FDA-2009-N-0667-0011,FDA,FDA-2009-N-0667,Memorandum of Understanding Between the Food and Drug Administration and Waterfront Media,Notice,N-Notice,2009-11-18T05:00:00Z,2009,11,2009-11-18T05:00:00Z,,2009-11-18T17:30:45Z,E9-27630,0,0,0900006480a5904e
FDA-1998-P-0974-0002,FDA,FDA-1998-P-0974,FDA/CDER - AstraZencea Pharmaceuticals LP - Withdrawl,Notice,NWL-Notice of Withdrawl,2009-11-17T05:00:00Z,2009,11,2009-11-17T05:00:00Z,,2009-11-17T15:33:19Z,,0,0,09000064805a24d1
FDA-1998-P-0974-0001,FDA,FDA-1998-P-0974,Gensia Sicor Pharmaceutical Inc - Comment,Notice,N-Notice,2009-11-17T05:00:00Z,2009,11,2009-11-17T05:00:00Z,,2013-07-27T21:47:33Z,,0,0,09000064805a24c3
FDA-2009-N-0664-0118,FDA,FDA-2009-N-0664,Oncologic Drugs Advisory Committee; Notice of Meeting,Notice,NM-Notice of Meeting,2009-11-17T05:00:00Z,2009,11,,,2009-11-17T17:38:38Z,E9-27493,0,0,0900006480a593d0
FDA-2009-N-0664-0119,FDA,FDA-2009-N-0664,General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting,Notice,NM-Notice of Meeting,2009-11-17T05:00:00Z,2009,11,,,2009-11-17T17:42:04Z,E9-27491,0,0,0900006480a5942c
FDA-2009-N-0664-0117,FDA,FDA-2009-N-0664,Oncologic Drugs Advisory Committee; Notice of Meeting,Notice,NM-Notice of Meeting,2009-11-17T05:00:00Z,2009,11,,,2009-11-17T17:35:10Z,E9-27490,0,0,0900006480a593f6
FDA-2009-N-0083-0012,FDA,FDA-2009-N-0083,Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Gluten-Free Labeling of Food Products Experimental Study,Notice,N-Notice,2009-11-17T05:00:00Z,2009,11,,,2009-11-17T17:30:25Z,E9-27512,0,0,0900006480a593b2
FDA-2009-N-0664-0115,FDA,FDA-2009-N-0664,Thermal Aspects of Radio Frequency Exposure; Public Workshop,Notice,NM-Notice of Meeting,2009-11-17T05:00:00Z,2009,11,,,2009-11-17T17:19:46Z,E9-27513,0,0,0900006480a59359
FDA-2009-N-0664-0116,FDA,FDA-2009-N-0664,National Mammography Quality Assurance Advisory Committee; Notice of Meeting,Notice,NM-Notice of Meeting,2009-11-17T05:00:00Z,2009,11,,,2009-11-17T17:23:57Z,E9-27492,0,0,0900006480a5937c
FDA-2000-D-1542-0001,FDA,FDA-2000-D-1542,Draft Guidance for Industry on the Content and Format of New Drug Applications and Abbreviated New Drug Applications for Certain Positron Emission Tomography Drug Products; Availability,Notice,NAD-Notice of Availability of Data,2009-11-16T05:00:00Z,2009,11,2009-11-16T05:00:00Z,2000-06-09T03:59:59Z,2009-11-16T19:37:14Z,,0,0,09000064804f9074
FDA-1998-N-0872-0001,FDA,FDA-1998-N-0872,Import for Export; Reporting and Recordkeeping Requirements for Unapproved or Violative Products Imported for Further Processing or Incorporation and Subsequent Export,Notice,Proposed Guidelines,2009-11-13T05:00:00Z,2009,11,1998-11-24T05:00:00Z,1999-02-09T04:59:59Z,2024-10-03T12:52:58Z,98-31351,0,0,09000064805a13c0
FDA-2008-N-0488-0025,FDA,FDA-2008-N-0488,Medical Devices: Ophthalmic Devices; Laser-Assisted In Situ Keratomileusis (LASIK) Devices; Reopening of the Comment Period,Notice,N-Notice,2009-11-13T05:00:00Z,2009,11,2009-11-13T05:00:00Z,2010-11-16T04:59:59Z,2009-11-13T15:03:26Z,E9-27222,0,0,0900006480a56cc2
FDA-2009-N-0292-0001,FDA,FDA-2009-N-0292,Michelle Lynn Torgerson; Debarment Order,Notice,N-Notice,2009-11-13T05:00:00Z,2009,11,2009-11-13T05:00:00Z,,2009-11-13T14:57:59Z,E9-27223,0,0,0900006480a56c08
FDA-1998-N-0872-0002,FDA,FDA-1998-N-0872,Import for Export; Reporting and Recordkeeping Requirements for Unapproved or Violative Products Imported for Further Processing or Incorporation and Subsequent Export; Marking Requirements for and Prohibitions on the Reimportation of Imported Food Products That Have Been Refused Admission Into the United States; Withdrawal,Notice,Withdrawal,2009-11-13T05:00:00Z,2009,11,,,2024-09-25T12:53:51Z,02-21264,0,0,09000064805a13ea
FDA-1998-D-0544-0001,FDA,FDA-1998-D-0544,Draft Modifications to Devices Subject to Premarket Approval - The PMA Supplement Decision Making Process; Availability,Notice,NAD-Notice of Availability of Data,2009-11-12T05:00:00Z,2009,11,2009-11-12T05:00:00Z,1998-11-05T04:59:59Z,2009-11-12T23:09:55Z,,0,0,090000648059b513
FDA-2009-D-0508-0009,FDA,FDA-2009-D-0508,Guidance for Industry on Registration and Product Listing for Owners and Operators of Domestic Tobacco Product Establishments; Availability,Notice,Notice of Availability,2009-11-12T05:00:00Z,2009,11,2009-11-12T05:00:00Z,,2024-11-07T22:12:04Z,E9-27182,1,0,0900006480a55f9e
FDA-1989-E-0386-0001,FDA,FDA-1989-E-0386,Determination of Regulatory Review Period for Purposes of Patent Extenion; Cytovene,Notice,N-Notice,2009-11-12T05:00:00Z,2009,11,2009-11-12T05:00:00Z,1989-11-28T04:59:59Z,2009-11-12T22:48:06Z,,0,0,090000648047a47c
FDA-2009-D-0528-0001,FDA,FDA-2009-D-0528,International Conference on Harmonisation; Draft Guidance on E7 Studies in Support of Special Populations; Geriatrics; Questions and Answers; Availability,Notice,NAD-Notice of Availability of Data,2009-11-10T05:00:00Z,2009,11,2009-11-10T05:00:00Z,2010-01-12T04:59:59Z,2009-11-10T17:26:33Z,E9-27000,0,0,0900006480a54e55
FDA-2009-N-0667-0009,FDA,FDA-2009-N-0667,"Memorandum of Understanding Between the Food and Drug Administration, United States Department of Health and Human Services and the National Oceanic and Atmospheric Administration, United States Department of Commerce",Notice,N-Notice,2009-11-10T05:00:00Z,2009,11,,,2009-11-10T17:42:24Z,E9-27118,0,0,0900006480a54f06
FDA-2008-D-0233-0029,FDA,FDA-2008-D-0233,Guidance for Industry: Use of Nucleic Acid Tests to Reduce the Risk of Transmission of West Nile Virus from Donors of Whole Blood and Blood Components Intended for Transfusion; Availability,Notice,NAD-Notice of Availability of Data,2009-11-09T05:00:00Z,2009,11,2009-11-09T05:00:00Z,,2009-11-09T17:00:09Z,E9-26870,0,0,0900006480a53fe0
FDA-2009-N-0506-0001,FDA,FDA-2009-N-0506,Agency Information Collection Activities; Proposed Collection; Comment Request; Bar Code Label Requirement for Human Drug and Biological Products,Notice,N-Notice,2009-11-06T05:00:00Z,2009,11,2009-11-06T05:00:00Z,2010-01-06T04:59:59Z,2009-11-06T17:06:28Z,E9-26850,0,0,0900006480a52a09
FDA-2009-D-0319-0001,FDA,FDA-2009-D-0319,Guidance for Industry and Food and Drug Administration Staff; In Vitro Diagnostic 2009 H1N1 Tests for Use in the 2009 H1N1 Emergency; Availability,Notice,NAD-Notice of Availability of Data,2009-11-06T05:00:00Z,2009,11,2009-11-06T05:00:00Z,,2009-11-06T17:16:29Z,E9-26737,0,0,0900006480a52aac
FDA-2009-N-0507-0001,FDA,FDA-2009-N-0507,Agency Information Collection Activities: Proposed Collection; Comment Request; Requirements for Submission of Labeling for Human Prescription Drugs and Biologics in Electronic Format,Notice,N-Notice,2009-11-06T05:00:00Z,2009,11,2009-11-06T05:00:00Z,2010-01-06T04:59:59Z,2009-11-06T17:11:19Z,E9-26760,0,0,0900006480a517ab
FDA-2009-D-0322-0001,FDA,FDA-2009-D-0322,Draft Guidance for Industry on Dosage Delivery Devices for Over-The-Counter Liquid Drug Products; Availability,Notice,NAD-Notice of Availability of Data,2009-11-05T05:00:00Z,2009,11,2009-11-05T05:00:00Z,2010-02-04T04:59:59Z,2009-11-05T15:22:21Z,E9-26531,0,0,0900006480a5173f
FDA-2009-N-0526-0001,FDA,FDA-2009-N-0526,Safe Use Initiative; Availability of Information,Notice,N-Notice,2009-11-05T05:00:00Z,2009,11,2009-11-05T05:00:00Z,,2024-11-07T22:08:15Z,E9-26530,1,0,0900006480a517a4
FDA-2009-N-0667-0007,FDA,FDA-2009-N-0667,"Amendment to Memorandum of Understanding Between the Food and Drug Administration and WebMD, LLC",Notice,N-Notice,2009-11-05T05:00:00Z,2009,11,2009-11-05T05:00:00Z,,2009-11-05T15:37:38Z,E9-26674,0,0,0900006480a51786
FDA-2007-C-0044-0003,FDA,FDA-2007-C-0044,Listing of Color Additives Exempt From Certification; Astaxanthin Dimethyldisuccinate,Notice,NFR-Notice of Final Rule,2009-11-05T05:00:00Z,2009,11,2009-11-05T05:00:00Z,2009-12-08T04:59:59Z,2026-01-08T20:58:38Z,E9-26524,0,0,0900006480a51773
FDA-2009-D-0347-0010,FDA,FDA-2009-D-0347,Draft Guidance for Industry: Guide to Minimize Microbial Food Safety Hazards of Melons; Extension of Comment Period,Notice,NEC-Notice of Extension,2009-11-04T05:00:00Z,2009,11,2009-11-04T05:00:00Z,2010-01-05T04:59:59Z,2009-11-04T15:37:25Z,E9-26638,0,0,0900006480a503a9
FDA-2009-D-0346-0013,FDA,FDA-2009-D-0346,Draft Guidance for Industry: Guide to Minimize Microbial Food Safety Hazards of Tomatoes; Extension of Comment Period,Notice,Extension of Comment Period,2009-11-04T05:00:00Z,2009,11,2009-11-04T05:00:00Z,2010-01-05T04:59:59Z,2019-02-28T14:03:35Z,E9-26636,0,0,0900006480a503a3
FDA-2009-D-0348-0014,FDA,FDA-2009-D-0348,Draft Guidance for Industry: Guide to Minimize Microbial Food Safety Hazards of Leafy Greens; Extension of Comment Period,Notice,NEC-Notice of Extension,2009-11-04T05:00:00Z,2009,11,2009-11-04T05:00:00Z,2010-01-05T04:59:59Z,2009-11-04T15:39:48Z,E9-26637,0,0,0900006480a503f7
FDA-2009-N-0519-0001,FDA,FDA-2009-N-0519,Public Workshop: International Conference on Harmonisation S2 Genetic Toxicology Issues; Request for Comments,Notice,NM-Notice of Meeting,2009-11-03T05:00:00Z,2009,11,2009-11-03T05:00:00Z,2010-02-25T04:59:59Z,2009-11-03T18:30:17Z,E9-26397,0,0,0900006480a4fe9e
FDA-2009-N-0523-0001,FDA,FDA-2009-N-0523,Product Tracing Systems for Food; Public Meeting,Notice,NM-Notice of Meeting,2009-11-03T05:00:00Z,2009,11,2009-11-03T05:00:00Z,2010-03-05T04:59:59Z,2010-03-04T22:10:42Z,E9-26479,0,0,0900006480a4fe7a